Methods of diagnosing and treating cervical cancer based on expression of farnesyl pyrophosphate synthase
Inventors
Checa Rojas, Alberto • Santillan Godinez, Orlando • Dominguez Palestino, Raul
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Assignees
Atso Corporate Affairs SA de CV • Timser SAPI De CV
Member
TIMSER S.A.P.I. de C.V.TIMSER S.A.P.I. de C.V. is a biomedical company in Mexico developing accessible and non-invasive blood-based screening solutions for early detection of cervical cancer and its precursor lesions. The company leverages more than a decade of research to advance clinically validated molecular diagnostics using protein biomarkers identified through proteomics and molecular biology approaches. These technologies address barriers to traditional screening and are backed by extensive national and international patent coverage and clinical trial validation involving hundreds of participants.
TIMSER S.A.P.I. de C.V. is a biomedical company in Mexico developing accessible and non-invasive blood-based screening solutions for early detection of cervical cancer and its precursor lesions. The company leverages more than a decade of research to advance clinically validated molecular diagnostics using protein biomarkers identified through proteomics and molecular biology approaches. These technologies address barriers to traditional screening and are backed by extensive national and international patent coverage and clinical trial validation involving hundreds of participants.
Publication Number
US-11160844-B2
Publication Date
2021-11-02
Expiration Date
Abstract
The present invention is related to diagnostic tests or rapid detections of different types of cancer, especially cervical cancer and precancerous lesions. Especially, the invention relates to specific and useful protein biomarkers for the detection of said diseases, and to the methods for determination and detection of said biomarkers.
Core Innovation
The invention provides a diagnostic and prognostic platform for cervical cancer based on detection of a panel of protein biomarkers, chiefly Farnesyl pyrophosphate synthase (FPPS/FDPS) with additional proteins having sequences shown as SEQ ID NOs 1–20 and variants with defined sequence identity of approximately ≥~70%. A long listing includes FPPS variants identified as SEQ ID NOs 21–27 and provides reference and control sequences for assay design and validation.
Acceptable samples include non-invasive sources such as blood, serum, plasma, urine, saliva and vaginal fluid, as well as cerebrospinal fluid, tear, biopsy and tissue. Detection modalities include [procedural detail omitted for safety]. A kit comprising a sample collection unit and a lateral flow device is disclosed, and FPPS sequences provide sequence targets for detection assays and probes.
The claimed method comprises detecting increased expression of FPPS in a sample from a subject, performing a biopsy to diagnose cervical cancer or a cervical lesion, and administering a treatment selected from specified agents. The disclosure states uses including diagnosis, staging, prognosis, predicting treatment response, treatment selection and monitoring, thereby integrating biomarker-based detection with diagnosis and treatment of cervical cancer or cervical lesions.
Claims Coverage
One independent claim is present and recites three main inventive features.
Detection of increased farnesyl pyrophosphate synthase expression
Detecting increased expression of farnesyl pyrophosphate synthase in a sample from a subject.
Biopsy to diagnose cervical cancer or a cervical lesion
Performing a biopsy to diagnose cervical cancer or a cervical lesion.
Administration of specified anticancer treatments
Administering a treatment to the subject, wherein the treatment is selected from the group consisting of cisplatin, carboplatin, paclitaxel, topotecan, docetaxel, ifosfamide, 5‑fluorouracil, irinotecan, gemcitabine, mitomycin, bevacizumab and pembrolizumab.
The independent claim covers detecting increased FPPS expression in a subject sample, performing a biopsy to diagnose cervical cancer or a cervical lesion, and administering one of a specified list of anticancer agents.
Stated Advantages
Enables diagnosis, staging, prognosis, treatment selection, predicting treatment response and monitoring for cervical cancer by detecting one or more biomarker polypeptides.
Ability to detect biomarkers in non-invasive sample types including blood, serum, plasma, urine, saliva and vaginal fluid.
Provides sequence targets for detection assays and probes for farnesyl pyrophosphate synthase.
Provides reference and control sequences for assay design and validation.
Provides a kit format including a sample collection unit and a lateral flow strip for biomarker detection.
Documented Applications
Diagnosis, staging, prognosis and treatment selection for cervical cancer by detecting one or more polypeptides or fragments with sequence identity to SEQ ID NOs 1-147, particularly SEQ ID NOs 1-20.
Detecting increased farnesyl pyrophosphate synthase expression in a sample from a subject.
Analyzing a variety of sample types for biomarker detection including blood, serum, plasma, urine, saliva, cerebrospinal fluid, tear, vaginal fluid, biopsy and tissue.
Using FPPS sequences as sequence targets for detection assays and probes.
Using listed FPPS and other sequences as reference and control sequences for assay design and validation.
Performing a biopsy to diagnose cervical cancer or a cervical lesion following detection of increased FPPS expression.
Administering a treatment selected from cisplatin, carboplatin, paclitaxel, topotecan, docetaxel, ifosfamide, 5‑fluorouracil, irinotecan, gemcitabine, mitomycin, bevacizumab and pembrolizumab following diagnosis.
Use of a lateral flow immunoassay kit comprising a sample collection unit and a lateral flow strip to detect biomarker polypeptides in biological samples.
Interested in licensing this patent?